Key result
Losartan pretreatment did not alter baseline alpha-adrenoceptor-mediated vasoconstriction but attenuated the enhanced response induced by exogenous Ang II.
Why the study?
Does losartan influence alpha-adrenoceptor-mediated vasoconstrictor response in healthy men?
Does losartan influence alpha-adrenoceptor-mediated vasoconstrictor response in healthy men?
Losartan does not directly affect alpha-adrenoceptor-mediated vasoconstriction but attenuates the enhancement of this response by exogenous Angiotensin II in healthy men.
Answers are grounded in this paper and cite their sources.
Losartan may selectively blunt Ang II-enhanced alpha responses without affecting baseline vasoconstriction in healthy men; hypothesis-generating for vascular interactions.
To evaluate the influence of losartan on alpha-adrenoceptor-mediated vasoconstrictor response, we examined dorsal hand vein constrictor response to phenylephrine (16-8,192 ng/min) and fingertip vasoconstrictor response to cold stimulation with and without pretreatment with losartan (50 mg/day) for 3 days in nine healthy men. The effect of coadministration of angiotensin II (Ang II) (0.3 ng/min) on the venoconstrictor response also was evaluated. Oral pretreatment with losartan alone influenced neither of the responses. The log of the infusion rate of phenylephrine producing half-maximal venoconstriction [log(ED50)] was 2.69 +/- 0.10 (mean +/- SEM) for control and 2.68 +/- 0.09 for losartan, and the reduction ratio of fingertip blood flow was 68.1 +/- 4.0% for control and 66.7 +/- 4.3% for losartan. Coadministration of Ang II, however, significantly enhanced the venoconstrictor response to phenylephrine [log(ED50): 2.43 +/- 0.09, p < 0.05 vs. control], and the pretreatment with losartan attenuated this effect [log(ED50): 2.60 +/- 0.11]. These findings indicate that the alpha-adrenoceptor-mediated vasoconstrictor response is not influenced by losartan; however, it is enhanced by exogenous Ang II, and losartan attenuates the enhanced response, in healthy human subjects.
No takes yet. Share an insight, caveat, or question.
Harada et al. (2000) studied Healthy (n=9). Losartan vs. Without pretreatment (control) was evaluated on Log of the infusion rate of phenylephrine producing half-maximal venoconstriction [log(ED50)]. Losartan pretreatment did not alter baseline alpha-adrenoceptor-mediated vasoconstriction but attenuated the enhanced response induced by exogenous Ang II.
Synapse has enriched 10 related papers. Consider them for comparative context: